Showing 1196 results
- Media Release /Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2] The landmark VERIFY study is…
- Key Release /Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has…
- Media Release /Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20…
- Media Release /Monitoring disease activity and treatment effectiveness in MS patients in real-time is a serious challenge for physicians New data show how the use of two central nervous system-derived…
- Media Release /New post hoc statistical analysis of the pivotal EXPAND study at ECTRIMS shows that Mayzent® (siponimod) can help patients keep their mobility for over four years longer on average *[1] …
- Media Release /Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent…
- Media Release /The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years…
- Media Release /Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…
- Media Release /Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading…
- Media Release /FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1 …
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 120
- › Next page